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Abstract
Background: We estimated the number of women undergoing cervical cancer screening annually
in Italy, the rates of cervical abnormalities detected, and the costs of screening and management of
abnormalities.
Methods: The annual number of screened women was estimated from National Health Interview
data. Data from the Italian Group for Cervical Cancer Screening were used to estimate the number
of positive, negative and unsatisfactory Pap smears. The incidence of CIN (cervical intra-epithelial
neoplasia) was estimated from the Emilia Romagna Cancer Registry. Patterns of follow-up and
treatment costs were estimated using a typical disease management approach based on national
guidelines and data from the Italian Group for Cervical Cancer Screening. Treatment unit costs
were obtained from Italian National Health Service and Hospital Information System of the Lazio
Region.
Results: An estimated 6.4 million women aged 25–69 years undergo screening annually in Italy (1.2
million and 5.2 million through organized and opportunistic screening programs, respectively).
Approximately 2.4% of tests have positive findings. There are approximately 21,000 cases of CIN1
and 7,000–17,000 cases of CIN2/3. Estimated costs to the healthcare service amount to €158.5
million for screening and €22.9 million for the management of cervical abnormalities.
Conclusion: Although some cervical abnormalities might have been underestimated, the total
annual cost of cervical cancer prevention in Italy is approximately €181.5 million, of which 87% is
attributable to screening.
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Background
Cervical cancer is the second most common cancer in
women worldwide and accounts for almost 10% of all
cancer-related deaths. In Italy, it is estimated that each
year 3,418 new cases and 1,186 deaths occur [1]. Infection
with Human Papillomavirus (HPV) has been established
as the necessary cause of cervical cancer [2,3]. As this can-
cer can be diagnosed at an early stage, screening programs
using the Papanicolaou (Pap) smear test have reduced sig-
nificantly the number of invasive cases, through the diag-
nosis and treatment of precancerous lesions (cervical
intraepithelial neoplasia, [CIN]) [4,5].
The Italian Ministry of Health establishes health-related
objectives at national level, while implementation is the
responsibility of regional governments. Some regions
started implementing cervical cancer screening programs
in the 1970s, while nationwide organized programs,
rolled out on a regional basis, were recommended in
1996, based on the European Commission Guidelines on
Quality Assurance in Cervical Cancer Screening [6]. By
1999, however, only 34% of Italian women aged 25–64
years were included [7]. In 2004, the Italian Government
ordered that each region should plan and implement cer-
vical cancer screening programs [8], to be provided by
Local Health Authorities. Such programs are still not fully
implemented across the country, although opportunistic
screening has increased. Two preventive cervical cancer
vaccines (Gardasil® and Cervarix®) are now registered in
Italy. In March 2008, a mass vaccination campaign tar-
geted at eleven-year-old girls was initiated, with some
regions vaccinating a second cohort of girls (14 or 15 year-
olds) and one region introducing a multi-cohort vaccina-
tion strategy, focused on four cohorts of girls aged 11, 14,
17 and 24 years.
In the absence of national data on the epidemiology of
cervical cancer screening in Italy, the present study was
undertaken to provide an estimation of the number of
women undergoing screening annually, the annual inci-
dence of cervical dysplasia, and direct costs associated
with the management of women diagnosed with cervical
dysplasia.
Methods
Estimation of the annual number of Pap smears in Italy
While organized screening programs publish the results of
their activity periodically, information on opportunistic
screening, i.e. Pap tests performed by public and private
providers but not included in a screening program, is
scarce. An estimation of the total number of women
screened annually was obtained from a survey performed
by the National Institute of Statistics (ISTAT) [9], which
provides data on Pap test use and screening intervals by
age and geographic area. The number of women screened
by screening interval was calculated by multiplying the
coverage (percentage) by the number of women aged 25–
69 years resident in Italy in 2005. To check the consistency
of our estimate, we used two recently published studies to
calculate the interval of screening (not shown) [10,11].
An alternative method, integrating data from the Italian
Group for Cervical Cancer Screening (GISCi) for compli-
ers and the ISTAT estimates for non-compliers, was used
to obtain a lower bound in sensitivity analysis; this second
hypothesis is based on the assumption that no women
had a Pap test (neither from organized nor from oppor-
tunistic settings) in the three-year interval.
Estimation of the annual number of abnormal Pap smears
Since 1997, the GISCi has been conducting surveys to
assess screening programs, which until 2006 collected
data on Pap tests and their results using the Bethesda Sys-
tem. The proportion of unsatisfactory samples and posi-
tive tests (including atypical squamous cells of
undetermined significance [ASCUS], low-grade squamous
intraepithelial lesions [LSIL], high-grade squamous
intraepithelial lesions [HSIL] and suspected carcinoma)
was obtained from the 2004 GISCi survey [11], and
applied to the estimated annual number of Pap smears.
To calculate the number of women referred for a repeat
Pap smear, the proportion of unsatisfactory smears
(6.1%) was applied to the total annual number of Pap
smears, and then multiplied by the compliance rate for
repeated cytology (62.2%), as observed in the GISCi sur-
vey [11].
Management of abnormal cytology and treatment of pre-
invasive lesions
To establish the typical management of abnormal cytol-
ogy and the management of cervical dysplasia, Italian and
international guidelines for cervical cancer screening were
reviewed. Published guidelines and protocols outlining
details of patient management were identified through
Medline Entrez-PubMed using the following search crite-
ria: 'uterine cervical neoplasms', 'uterine cervical dyspla-
sia', 'cervical intraepithelial neoplasia' AND 'screening';
the search was limited to 'practice guidelines'. In addition,
a search of Embase and the Cochrane database was con-
ducted using the search terms 'uterine cervix cancer' and
'uterine carcinoma in situ'.
The initial Medline search, concluded on 30 July 2006,
gave 77 hits; a review of corresponding abstracts excluded
57 irrelevant, non-English or non-Italian articles. The
Embase search did not add any new item. The reference
sections of each identified article were checked for further
guidelines (one additional item found). A screening of
governmental agencies and Italian scientific societies
identified 12 additional items. Agencies include the Ital-
ian National Health Agency (AgeNaS) and regional web-BMC Public Health 2009, 9:71 http://www.biomedcentral.com/1471-2458/9/71
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sites of Emilia Romagna, Piemonte, Veneto, Toscana,
Lazio, Basilicata. The web database of the following inter-
national and national agencies was reviewed: IARC (Inter-
national Agency for Research on Cancer), NHS (National
Health Service) Cervical Screening Programme and NICE
(National Institute for Clinical Excellence) UK, ANAES
(Agence Nationale d'Accréditation et d'Évaluation en
Santé) France, National Cervical Screening Programme
New Zealand. The following Italian scientific societies
were identified: GISCi (Italian Group for Cervical Cancer
Screening), ONS (National Centre for Screening Monitor-
ing), AIE (Italian Association of Epidemiology), SICi (Ital-
ian Society of Cytology), SICPCV (Italian Society of
Cervical Pathology and Colposcopy) and SIAPEC (Italian
Society of Pathology and Cytodiagnostics).
Estimation of the annual number of CIN1 and CIN2/3 
diagnoses
In order to estimate the number of CIN1 lesions diag-
nosed each year, the CIN1 detection rate reported in the
GISCi survey [11] was applied to the total number of Pap
smears performed annually, although only 40 centres out
of 95 organized cervical cancer screening programs partic-
ipating in the GISCi survey registered data on CIN1 [12].
Two methods were used to estimate the number of CIN2/
3 lesions. Method 1 was based on data from the Emilia
Romagna Cancer Registry [13], the only Italian cancer reg-
istry providing reliable data on pre-invasive lesions. The
detection rate was calculated by dividing the number of
lesions by the estimated number of women screened in
the same area and time period. This rate was then applied
to the estimated total number of Pap smears performed
annually in Italy. Method 2 applied the detection rate of
CIN2/3 from the GISCi survey [11] to the total annual
number of Pap smears. Currently, the number of CIN2,
CIN3 and invasive carcinoma are reported in 75 out of 95
organized cervical cancer screening programs in Italy. The
relative proportions of such lesions that were attributable
to CIN2 and CIN3 were determined according to the
results of the GISCi survey of second level screening for
cervical cancer [12]. Both sources, the survey and the can-
cer registry, collect histological results according to the
Richart classification for CIN.
Costs associated with cervical screening and treatment of 
cervical dysplasia
To calculate the total annual cost of cervical cancer screen-
ing from the healthcare perspective, unit costs for the rel-
evant procedures were applied to the estimated numbers
for total Pap tests and for women with each type of abnor-
mal cervical cytology, based on the National Tariff Formu-
laries [14] (Table 1). For women who had Pap tests
performed within a screening program, there was an addi-
tional cost pertaining to each test invitation [[15]; ASP
Lazio, unpublished data]. A cost for gynaecologic exami-
nation was added to the cost of Pap tests performed out-
side the screening program. Disruptive treatments for CIN
(e.g. laser vaporization, cryotherapy, diathermocoagula-
tion) were considered outpatient procedures.
It was assumed that excisional treatments for CIN (radiof-
requency excision, cold-knife excision and laser conisa-
tion) were performed in hospital, either as day-hospital or
inpatient procedures, and costs for these procedures were
Table 1: Unit costs for invitation, diagnostic procedures and treatments.
Procedure Formulary code
(Lazio region)
Tariff (€)
Invitation for screening (not included in formularies) 3.33
Diagnostic
Pap test (conventional smear) 91.38.5 11.16
HPV test 91.37.01 81.60
Colposcopy 70.21 10.74
Endocervical biopsy 67.11 24.79
Histological evaluation of vaginal biopsy 91.45.5 14.10
Gynecologic examination 89.26 13.63
Treatments
Disruptive
Laser vaporization 67.39 None
Cryotherapy 67.33 37.18
Excisional
Leep, cold blade and surgical conisation DRG code 630
Day hospital 913.85
Full hospitalization 1,516.84
Leep: loop electrical excision procedureBMC Public Health 2009, 9:71 http://www.biomedcentral.com/1471-2458/9/71
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obtained from the Lazio Hospital Discharge Registry
(Table 1). All costs are reported in 2005 euros.
Sensitivity analysis
A sensitivity analysis was performed for five parameters:
1. For the total number of Pap tests, we used as lower
bound of the estimate the result of a mixed method that
includes the GISCi survey data and excludes overlaps
between organised and opportunistic screening in the
three-year period.
2. For the number of CIN2/3, we used the extrapolation
from the GISCi survey as the higher bound of the esti-
mate.
3. We varied the rate of referral to colposcopy from the
value observed for the 25th centile of the programmes dis-
tribution of the GISCi survey to the 75th centile of this dis-
tribution.
4. We report the result of a hypothetical massive introduc-
tion of HPV testing for the triage of ASCUS, using the fol-
lowing assumptions: all ASCUS are referred to HPV test;
the compliance to HPV test is 89% (as for colposcopy);
the proportion of HPV positive among ASCUS is 24.2%
[16]; the proportion of CIN1/2/3 consequent to ASCUS
diagnosis among the total CIN1/2/3 in ASCUS + LSIL is
41% [16]; the biopsy rate among ASCUS HPV+ is arbitrar-
ily set to 90%; the HPV test cost is 81.60€ as national tariff
and arbitrarily 15€ in the prevision of a strong price
reduction.
5. Since the tariff of colposcopy is one of the lowest in
industrialised countries, we report the total costs under
the assumption that in opportunistic screening, colpos-
copy is always associated to a gynaecological visit.
6. We report the total costs under the assumption of an
inverted proportion of CIN1 treated (i.e. 63% instead of
37%).
7. We report the total costs under the extreme hypothesis
of all conisations performed in outpatient settings. This
does not apply to the conisations for recurrence.
Results
Estimation of the annual number of Pap smears in Italy
Our calculations suggest that a total of 6,423,924 women
aged 25–69 years undergo screening on an annual basis in
Italy (Table 2). According to ISTAT, there are approxi-
mately 16.5 million Italian women aged 25–64 years and
therefore eligible for organized cervical screening. Given
the recommended 3-year screening interval, approxi-
mately 5.5 million women (one-third of the target popu-
lation) should be invited for cervical screening each year.
However, screening programs only contact approximately
2.8 million women each year and 1.2 million of these
women are actually screened [11]. These latter figures cor-
respond to 27.5% and 11.8%, respectively, of the female
target population living in areas having active screening
programs. Although the number of projected screened
women includes some women beyond the recommended
age for screening, it can be estimated that approximately
5.2 million women in Italy undergo opportunistic screen-
ing.
From a total of approximately 6.4 million women who
undergo screening, it is estimated that about 390,000
have unsatisfactory results and, as a consequence, approx-
imately 240,000 have a repeated test (Table 2). Overall,
approximately 6 million women have a cytological result
that permits assessment of their risk of cervical cancer.
Estimation of the annual number of cytological 
abnormalities
According to the GISCi survey 2004, 2.4% of Pap tests
were positive [11]. By applying this proportion to the esti-
mated number of satisfactory tests, we estimate that
153,393 women have a positive result (Table 3). The most
frequent finding is ASCUS, followed by LSIL.
Management of women with abnormal cytology
Twenty nine guidelines about screening and management
of abnormal Pap tests were identified and reviewed. All
current Italian guidelines recommend the TBS classifica-
tion for cytology results (version 1991 followed by 2001).
The management of LSIL, HSIL and suspected carcinoma
is clearly defined: colposcopy and, if positive, biopsy.
Conversely, ASCUS has three acceptable management
options: colposcopy, repeat cytology at 6 months or HPV
triage. On the basis of the GISCi data [11] and expert
opinion, only direct referral to colposcopy was considered
for the management of ASCUS. For HSIL, it was assumed
that 90% of cases would undergo biopsy, but overall
49.6% of abnormal cases referred for colposcopy also
underwent biopsy, as reported by GISCi [11]. We esti-
mated that, of the 153,393 women with abnormal cytol-
ogy, 134,054 would undergo colposcopy and 66,450
would have a biopsy.
Table 2: Estimated annual number of Pap smears in women aged 
25–69 years, Italy 2005.
Number %
Total number of women 6,423,924 100.00
Satisfactory Pap smears 6,034,550 93.9
Unsatisfactory Pap smears 389,376 6.1
Repeat Pap smears 242,194 --
Total number of Pap smears 6,666,118 --BMC Public Health 2009, 9:71 http://www.biomedcentral.com/1471-2458/9/71
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There is no consensus guideline on the duration and fre-
quency of follow-up of negative findings by colposcopy
and biopsy. It was assumed that the typical follow-up for
women with negative findings by colposcopy after LSIL or
less severe cytological results was a Pap test after one year.
The typical follow-up for negative colposcopy findings
after HSIL or more severe cytological results was assumed
to be two colposcopies with a repeated Pap test.
Cost of cervical screening and management of abnormal 
Pap tests
The total cost of cervical screening in Italy was estimated
to be €158.5 million annually (Table 4). Most of these
costs were associated with opportunistic screening. The
costs of additional tests in women with an abnormal Pap
smear were estimated to be approximately €4.0 million in
the first year and €5.2 million including the costs of fol-
low-up (Table 5). Most of these costs were attributable to
women with ASCUS/LSIL. However, the unit cost per
patient was higher for HSIL/carcinoma than for ASCUS/
LSIL (Table 5).
Estimation of the annual number of CIN1 and CIN2/3 
diagnosed in Italy
It was estimated that 21,308 CIN1 lesions are diagnosed
each year in Italian women. Estimates based on data from
the Emilia Romagna Cancer Registry (Method 1) sug-
gested that 6,982 CIN2/3 lesions are diagnosed annually:
3,218 cases of CIN2; 3,518 cases of CIN3; and 245 cases
of adenocarcinoma in situ (AIS). These data excluded
women aged less than 24 years, for whom there is no esti-
mate. The GISCi survey (Method 2) provided a substan-
tially higher estimate for the total incidence of CIN2/3 of
16,571 cases (7,638 CIN2; 8,350 CIN3; 583 AIS) and 738
invasive cancers, resulting in a detection rate of 2.7/1000.
The estimated incidence of AIS and invasive adenocarci-
noma is lower than for squamous cell lesions. It was esti-
mated that there would be 274 cases with recurrent CIN2
and 333 cases with recurrent CIN3 during a 2-year follow-
up period.
Management of cervical dysplasia (CIN)
Sixteen guidelines about treatment of pre-invasive lesions
were identified and reviewed. All current Italian guide-
lines recommend the Richart (CIN) classification for his-
tology. A few Italian guidelines specifically refer to the
treatment of CIN lesions. These include the Italian Society
of Cervical Pathology and Colposcopy, the Italian Society
for Gynaecology and Obstetrics (SIGO), the Society for
Gynaecology and Obstetrics of Lombardy (SLOG) and
those of the Emilia Romagna and Tuscany Regions. A
review of these guidelines revealed three points where
management practices may vary. First, it is recommended
that CIN1 lesions should be followed up and treated only
if persistent, or alternatively when the colposcopy is
incomplete or the lesion is not completely visible. How-
ever, the GISCi survey found that the proportion of
treated CIN1 lesions varies extremely between different
centres [12].
Consequently, the overall percentage of treated CIN1
lesions from the GISCi survey (37%) was used for all anal-
yses. Secondly, guidelines recommend excision as the pre-
ferred treatment option for all grades of CIN, although the
use of disruptive surgery is also allowed in some cases.
Our estimates were based on the percentage of excisions
and disruptive treatments observed in the GISCi survey
for each CIN grade [12]. For CIN1, 63.0% of cases had no
immediate treatment (follow-up cytology and colposcopy
at 6 months), 20.3% had disruptive treatment (29% laser
vaporization and 71% diathermocoagulation) and 16.7%
had excisional treatments. For CIN2/3, 3.7% and 96.3%
of cases had disruptive and excisional treatment, respec-
Table 3: Estimated cytology results for women aged 25–69 with a satisfactory Pap smear, Italy 2005.
Cytology finding n % Positive % Diagnosis
Total number of satisfactory cytological diagnoses 6,276,744 100.0 --
Negative 6,123,349 97.6 --
Positive 153,393 2.4 100.0
ASCUS 68,161 1.09 44.4
LSIL 44,539 0.71 29.0
HSIL 11,976 0.19 7.8
Carcinoma 678 0.01 0.4
Other1 28,039 0.45 18.3
1Includes women referred for colposcopy after two unsatisfactory Pap smears
Table 4: Estimated annual costs of detection and management of 
cervical dysplasia (including follow-up), Italy 2005.
Annual cost (€)
Total screening costs 158,541,733
Screening program
Cost of invitations 9,293,041
Cost of Pap smears 13,104,094
Opportunistic screening 130,140,608
Repeated Pap smears 6,003,989BMC Public Health 2009, 9:71 http://www.biomedcentral.com/1471-2458/9/71
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tively. The third point of discrepancy between guidelines
is the duration and intensity of follow-up for CIN2/3 after
treatment. It was assumed that all women would have had
a repeat Pap test and colposcopy every 6 months for 2
years, as recommended in the guidelines from the Emilia
Romagna Region. The estimated proportion of cases with
recurrent CIN after treatment for CIN2/3 was based on
findings reported in the study by Cecchini [17]. Any con-
troversial points were discussed with an expert panel.
Costs of cervical dysplasia treatment
Using the lower estimate for the incidence rate of CIN2
and CIN 3, the total annual cost of treating CIN was €16.4
million, excluding any follow-up costs, and €17.8 million
when follow-up costs were included. Treatment of CIN3
accounted for almost half of all costs (Table 5). The over-
all unit costs per patient were estimated to be €579 and
€628, excluding and including costs of follow-up, respec-
tively. The unit cost increased with disease severity.
If the higher estimates for incidence of CIN2 and CIN3 are
used, the estimated costs of treatment (including follow-
up) increase to €11.8 million and €19.3 million, respec-
tively, and the overall cost of managing CIN could be as
high as €36.7 million.
The combined cost of diagnosis and treatment of cervical
lesions is €22.9 million, if the costs of follow-up are
included (Table 5). When the costs of screening are
included, the total annual cost of the cervical screening
program amounts to €181.5 and €200.5 million, respec-
tively, when the lower and the higher CIN2/3 incidence
rates are considered.
Sensitivity analysis
The most influential parameters are the number of CIN2/
3, which increases the total cost by 6.4%, and the setting
for conisation, that can reduce the total costs up to 11.1%
(Table 6).
Discussion
Our study suggests that costs associated with the detection
and treatment of cervical dysplasia are substantial. Each
year the Italian healthcare service is expected to spend
€181.5 million (€200.5 million if the higher incidence of
CIN2+ lesions is taken into account) to screen approxi-
mately 6.4 million women aged 25–69 years, to manage
more than 150,000 women with abnormal Pap smears,
and to treat an estimated 21,000 women with CIN1
lesions and 7,000–17,000 women with CIN2/3 lesions.
Although the majority of these costs are directly related to
cervical screening, only a small proportion is attributable
to organized screening programs, with opportunistic test-
ing accounting for the greatest share of costs. In contrast,
our estimates suggest that only 11% of the total healthcare
costs are associated with the management of CIN lesions;
this percentage increases to 18% if the higher CIN2/3 inci-
dence rate is applied.
Interestingly, although approximately 6.4 million women
have a Pap test each year, which should cover the target
population for organized screening, there are still 30% of
women who had no Pap test in the last three years. Only
1.2 million women are screened within organised pro-
grams, but approximately 5.2 million are screened oppor-
tunistically. This suggests that some women are screened
more frequently than the recommended 3-year interval,
while others are screened despite being older than the rec-
ommended age, whereas some women may never be
screened. This is consistent with analyses from the ISTAT
data, showing that up to 50% of women in Southern Italy
and the Italian islands have never been screened, com-
pared with approximately 25% of women in Northern
and Central Italy [18].
Table 5: Estimated total and unit costs for diagnosis of abnormal Pap smears and treatment of CIN, Italy 2005.
First year Total cost
(First year and follow-up)
Total cost (€)U n i t  c o s t  ( €)T o t a l  c o s t  ( €)U n i t  c o s t  ( €)
Diagnosis 3,986,007 20.1 5,179,506 33.8
ASCUS/LSIL 2,780,336 24.7 3,595,139 31.9
HSIL/carcinoma 499,034 41.7 602,402 50.3
Others 706,637 24.6 981,965 34.2
CIN treatment 16,381,037 579.1 17,779,760 628.5
CIN11 4,819,842 226.2 5,580,319 261.9
CIN22 4,336,532 1347.7 4,630,430 1439.1
CIN32 7,224,664 1919.4 7,569,011 2010.9
Total 20,367,044 22,959,267
1Estimate based upon data from the GISCi 2004 survey [12]; 2Estimate based upon data from the Emilia Romagna Cancer Registry [13].BMC Public Health 2009, 9:71 http://www.biomedcentral.com/1471-2458/9/71
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This study has several limitations. Firstly, extrapolation of
GISCi data to the whole Italian female population may
result in an overestimation of the number of women
screened and in an underestimation of CIN management.
Secondly, although the GISCi survey represents the only
available data relating to screening programs from differ-
ent Italian regions, this data collection system neither
includes opportunistic screening carried out in the private
setting, nor takes into account data from each Italian
region. Furthermore, some Italian regions do not yet have
formalized screening programs, and data included in the
GISCi survey 2004 [11,12] are, therefore, collected exclu-
sively in regions with well-established programs. Thirdly,
the absence of any national data on opportunistic screen-
ing, which accounts for the majority of screening in Italy,
also limits estimates of the epidemiology of cervical dys-
plasia. Lastly, we could not estimate the number of cases
of CIN2/3+ for women younger than 24 years of age and
older than 70 years. Although a small proportion of
CIN2/3+ occurs in women under 24 years of age, such
lesions are very likely to regress [19] and, according to
guidelines, should not be diagnosed [8]. Conversely, very
few women over 70 years of age have Pap smears. Our cal-
culations assume that in situ lesions detected in women
older than 69 years, as reported by the Emilia Romagna
Cancer Registry, can be attributed to Pap smears per-
formed in women aged 65–69 years.
The two methods used to estimate the annual number of
CIN2/3 lesions produced markedly different values.
Method 1, based on data from the Emilia Romagna Can-
cer Registry, suggested that there are about 7,000 cases of
CIN2/3 diagnosed. However, data drawn from a single
registry cannot have 100% sensitivity to accurately project
the incidence of these lesions nationwide, especially as
this data collection is relatively new and does not have
Table 6: Univariate sensitivity analysis of screening, abnormal findings management and treatment costs (€), Italy 2006.
Screening Abnormal findings and treatment Total costs of cervical cancer
prevention
Baseline values for all the parameters 158,288,703 22,959,267 181,247,970
No. of screened women yearly
baseline: extrapolation from ISTAT 
(N = 6,423,924)
lower case: similar, but excluding overlap 
between opportunistic and organised 
screening (N = 6,270,130)
154,332,393 22,825,230 177,157,624
No. of CIN2/3 found
baseline: estimate from Emilia Romagna 
cancer registry (N = 6,982)
higher case: extrapolation from GISCi 
survey (N = 16,571)
158,288,703 34,532,811 192,821,515
Referral rate
baseline: extrapolation from GISCi survey 
(2.5%)
lower case: 25th centile of the GISCi 
survey distribution (1.5%)
158,288,703 20,920,849 179,209,552
higher case: 75th centile of the GISCi 
survey distribution (3%)
158,288,703 24,235,135 182,523,838
ASCUS management
baseline: no triage with HPV test
triage with HPV test (cost 81.60€ 
according to national tariff)
158,288,703 26,101,216 184,389,919
triage with HPV test (cost 15.00€) 158,288,703 22,197,251 180,485,954
Colposcopy setting
baseline: no gynaecological visit
upper case: gynaecological visit for 
colposcopies performed in opportunistic 
screening
158,288,703 25,199,706 183, 488,409
CIN1 treatment
baseline: 37% of CIN1 treated
upper case: 63% of CIN1 treated 158,288,703 26,231,936 184,510,639
Conisation setting
baseline: inpatient 
(36% day hospital and 64% full 
hospitalization)
lower case: outpatient 158,288,703 8,084,711 166,373,414BMC Public Health 2009, 9:71 http://www.biomedcentral.com/1471-2458/9/71
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well-established quality indicators, such as for invasive
cancer. The value derived using Method 1 can, therefore,
be used as a lower limit of the CIN2/3 range. Method 2,
which used data from the GISCi survey, suggested that
there are more than 17,000 cases of CIN2+ diagnosed
each year. This number might overestimate the incidence
rate, as the detection rate observed in organized screening
programs using a 3-year interval is probably higher than
the detection rate of opportunistic screening, often based
on a 1-year interval. This estimate can, therefore, be used
as the upper limit of the CIN2/3 range. In our sensitivity
analysis, this parameter appeared to be one of the most
influential, resulting in the highest cost estimate (+ 6.3%).
With reference to the annual expected number of CIN1, it
should be noted that only 42.1% (40 out of 95) of centres
participating in the GISCi survey systematically provide
data. Although these lesions do not generally require
treatment, it is commonly agreed in clinical practice, par-
ticularly in opportunistic screening, that deviations from
best practice are frequent and over-treatment is often per-
formed. Consequently, the impact of CIN1 treatment on
costs might have been underestimated.
In the cost calculations, it was assumed that all women
with ASCUS would be referred directly for colposcopy,
although this is not entirely consistent with current guide-
lines or clinical practice. However, the introduction of
HPV triage does not change substantially the total costs, as
shown by the sensitivity analysis. Nevertheless, estima-
tion of the costs of additional diagnostic procedures for
LSIL and HSIL and for treatment of CIN was based on
practices reported in the GISCi survey, so may be consid-
ered representative of current practice in Italy.
The shift of treatment procedures to a more appropriate
setting of care, in particular conisation from inpatient to
outpatient is currently the most suitable way to reduce
total costs of disease. Nevertheless, a change in the setting
of surgery from day hospital to outpatient has a strong
impact if tariffs are used to measure costs, but this is an
overestimation of the real impact on the real costs sus-
tained by the Health Service.
Although it is not possible to make direct cost compari-
sons between different healthcare systems, it is interesting
to note that the costs of cervical screening in Italy are com-
parable with those for England, where approximately 4
million women are screened each year at a cost of €157
million (approximately €200 million), including the cost
of treating abnormalities [20]. However, the estimated
cost per case associated with CIN1 treatment in the
present study was lower in comparison with the mean
cost reported in England and Wales (€419; approximately
€532), whereas the estimated unit costs for CIN2 and
CIN3 were considerably higher than the mean costs
(€572 [approximately €726] and €606 [approximately
€770], respectively) [21].
As the focus of this study was the economic burden of cer-
vical dysplasia, our calculations did not take into account
societal costs, such as work loss due to screening or for
CIN treatment. We also did not capture the psychological
burden of receiving a positive Pap smear result.
Until recently, regular screening was the only tool to pre-
vent cervical cancer. The development of HPV vaccines
has provided a new opportunity to reduce the incidence of
cervical dysplasia [22-24] and studies have shown that a
combination of both vaccination and screening is a cost-
effective solution to reduce morbidity and mortality
caused by cervical cancer [25-28].
Conclusion
This is the first study to assess the epidemiology of cervical
cancer screening and cervical dysplasia, as well as the asso-
ciated healthcare costs, for Italy as a whole. Each year, the
Italian healthcare service system makes a substantial
investment of €158.5 million for the provision of screen-
ing services and €22.9 million for the follow-up and treat-
ment of cervical abnormalities.
Higher adhesion to guidelines and protocols would pro-
duce substantial savings. Although the number of Pap
tests performed each year would be sufficient to cover the
whole target population, 30% of women are still not
screened.
The economic burden of disease associated with cervical
dysplasia identified in this study will assist health author-
ities with both the planning and allocation of funding for
an effective cervical cancer prevention strategy.
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